| HOME | MEETINGS | MEMBERSHIP | EXHIBITORS | AWARDS | INFO | NEWS | ABOUT US | CONTACT | SIGN IN |
ensuring knowledge, enhancing quality
A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts
run for pharmaceutical analysts by pharmaceutical analysts
| HOME | MEETINGS | MEMBERSHIP | EXHIBITORS | AWARDS | INFO | NEWS | ABOUT US | CONTACT | SIGN IN |
NEXT EVENT: Thursday 13th October 2016 - Good Distribution Practice: solving implementation and quality issues... 
JPAG - serving its members since 1970
JPAG plans and delivers events that address all aspects of pharmaceutical analysis and related facets of medicine control & registration.
NEXT EVENTS:
LAST EVENT:
JPAG plans and delivers events that address all aspects of pharmaceutical analysis and related facets of medicine control & registration.
NEXT EVENTS:
Thursday 13th October 2016
Good Distribution Practice: solving implementation and quality issues
Royal Society of Chemistry, London
In a globalised healthcare ecosystem, supply chains become more complex, with an increased potential for quality issue to arises. So, it is critically important to understand Good Distribution Practices (GDP) and the requirements for shared responsibilities throughout the entire supply chain.
This symposium will examine the regulatory requirements of GDP, provide an understanding of the issues and demonstrate how common problem can be overcome.
Speakers:
Julia Claus - Pfizer
Afshin Hosseiny - Tabriz Consulting
Christopher Jones - AstraZeneca
Philip Neale - MHRA
Paul O'Connor - Almac Group
Fiona Routley - AstraZeneca
Emma Thomson - Mawdsleys Clinical Services
Dr Manuel Zahn - 3R Pharma Consulting GmbH
DETAILS AND BOOKING
Good Distribution Practice: solving implementation and quality issues
Royal Society of Chemistry, London
In a globalised healthcare ecosystem, supply chains become more complex, with an increased potential for quality issue to arises. So, it is critically important to understand Good Distribution Practices (GDP) and the requirements for shared responsibilities throughout the entire supply chain.
This symposium will examine the regulatory requirements of GDP, provide an understanding of the issues and demonstrate how common problem can be overcome.
Speakers:
Julia Claus - Pfizer
Afshin Hosseiny - Tabriz Consulting
Christopher Jones - AstraZeneca
Philip Neale - MHRA
Paul O'Connor - Almac Group
Fiona Routley - AstraZeneca
Emma Thomson - Mawdsleys Clinical Services
Dr Manuel Zahn - 3R Pharma Consulting GmbH
DETAILS AND BOOKING
Thursday 1st December 2016
Regulatory Hot Topics II
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines.
It will provide the opportunity for dialogue and discussion through an effective forum to understand, interpret and translate into day-to-day practice on topics including: ICH Q3D; ICH Q12; continuous manufacture; excipient GMP; allowable flexibility in analytical methods; development and filing of a breakthrough status medicine; microbiological quality of non-sterile dosage forms (USP 1111 and 1115)
Speakers:
Dr Gurjit Bajwa - GSK
Dr Paul Butterworth - AZ
Dr Graham Cook - Pfizer
Dr David Elder - JPAG/consultant
Ewan Norton - MHRA
Dr Stephen Smith - AZ
Dr Andrew Teasdale - AstraZeneca
DETAILS AND BOOKING
Regulatory Hot Topics II
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines.
It will provide the opportunity for dialogue and discussion through an effective forum to understand, interpret and translate into day-to-day practice on topics including: ICH Q3D; ICH Q12; continuous manufacture; excipient GMP; allowable flexibility in analytical methods; development and filing of a breakthrough status medicine; microbiological quality of non-sterile dosage forms (USP 1111 and 1115)
Speakers:
Dr Gurjit Bajwa - GSK
Dr Paul Butterworth - AZ
Dr Graham Cook - Pfizer
Dr David Elder - JPAG/consultant
Ewan Norton - MHRA
Dr Stephen Smith - AZ
Dr Andrew Teasdale - AstraZeneca
DETAILS AND BOOKING
Thursday 9th February 2017
Dissolution testing: current and future considerations
Royal Society of Chemistry, London
Dissolution and disintegration tests for solid oral dosage forms provide insight into the rate of release of the drug into the body. Dissolution has been viewed solely as a quality control tool, but more recently this view has started to change and now there is clear expectation that dissolution must have clinical relevance.
However, the challenge remains: how can a single test be sensitive enough to predict changes that may be of clinical relevance, whilst being robust enough to satisfy the needs of a quality control environment?
This symposium will explore the current state of these techniques from a regulatory, pharmacopoeia, academic and industry perspective, and how emerging bio-relevant dissolution tools can improve our prediction of oral drug behaviour.
This symposium should be attractive to scientists working in research & development, quality control, regulatory, pharmacopoeias and academia. In addition senior managers will benefit from attending.
This symposium is organised in association with the OrBiTo consortium.
Speakers:
Dr Karl Box - Sirius Analytical
Dr Karin Bracht - MHRA
Dr James M Butler - GSK
Dr David Elder - JPAG/consultant
Dr Edmund Kostewicz - Frankfurt University
Dr James C Mann - AZ
Catherine Pitt - MHRA
Dr Axel Zeitler - Cambridge University
DETAILS AND BOOKING
Dissolution testing: current and future considerations
Royal Society of Chemistry, London
Dissolution and disintegration tests for solid oral dosage forms provide insight into the rate of release of the drug into the body. Dissolution has been viewed solely as a quality control tool, but more recently this view has started to change and now there is clear expectation that dissolution must have clinical relevance.
However, the challenge remains: how can a single test be sensitive enough to predict changes that may be of clinical relevance, whilst being robust enough to satisfy the needs of a quality control environment?
This symposium will explore the current state of these techniques from a regulatory, pharmacopoeia, academic and industry perspective, and how emerging bio-relevant dissolution tools can improve our prediction of oral drug behaviour.
This symposium should be attractive to scientists working in research & development, quality control, regulatory, pharmacopoeias and academia. In addition senior managers will benefit from attending.
This symposium is organised in association with the OrBiTo consortium.
Speakers:
Dr Karl Box - Sirius Analytical
Dr Karin Bracht - MHRA
Dr James M Butler - GSK
Dr David Elder - JPAG/consultant
Dr Edmund Kostewicz - Frankfurt University
Dr James C Mann - AZ
Catherine Pitt - MHRA
Dr Axel Zeitler - Cambridge University
DETAILS AND BOOKING
LAST EVENT:
EXTERNAL EVENT: Friday 30th September 2016
Peri-operative Medicines Management Masterclass
RPS, East Smithfield, London
DETAILS AND MATERIALS
Peri-operative Medicines Management Masterclass
RPS, East Smithfield, London
DETAILS AND MATERIALS
Our only sponsors are our parent professional bodies:
Delegates of any JPAG symposia can access the speakers presentations.
Just SIGN IN, go to RESOURCES and look in MY PAST MEETINGS.
Just SIGN IN, go to RESOURCES and look in MY PAST MEETINGS.
Missed the meeting?
You can access a short report of recent meetings!
Just go to the MEETINGS page, go to PAST MEETINGS 2011-present. Then select the DETAILS for the meeting that interests you.
And do be sure to check the list of upcoming meetings so that you don't miss the next one!
You can access a short report of recent meetings!
Just go to the MEETINGS page, go to PAST MEETINGS 2011-present. Then select the DETAILS for the meeting that interests you.
And do be sure to check the list of upcoming meetings so that you don't miss the next one!
European Pharmaceutical Review
JPAG members can receive a free hard copy subscription to EPR
click here
JPAG members can receive a free hard copy subscription to EPR
click here
TESTIMONIALS:
Excellent meeting, challenging and thought provoking. The organisation was excellent, thanks to all the efforts that JPAG team have made (March 2015)
I have not attended a bad JPAG meeting yet. They are really good value for money and I really love to get the presentations as PDFs (June 2015)
LATEST NEWS:
The 2016 Geoffrey Phillips Analytical Science Award
Mr Husain Naqi, University of Bath, was awarded the Geoffrey Phillips Analytical Science Award 2016 for the best podium presentation at the APS Conference on Monday 5th September, held at the University of Strathclyde.
The paper presented by Husa...
More...
Monday 12th September 2016
Mr Husain Naqi, University of Bath, was awarded the Geoffrey Phillips Analytical Science Award 2016 for the best podium presentation at the APS Conference on Monday 5th September, held at the University of Strathclyde.
The paper presented by Husa...
More...
Monday 12th September 2016
EPR health-based exposure limits for cleaning qualification
Here is the latest article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "New regulatory strategies to address un-met clinical needs" written by Dr Dave Elder, Chairman of the JPAG Committee. More...
Friday 9th September 2016
Here is the latest article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "New regulatory strategies to address un-met clinical needs" written by Dr Dave Elder, Chairman of the JPAG Committee. More...
Friday 9th September 2016
Biosimilars: future prospects
Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (mABs), are playing an increasingly
important role in global healthcare. It was recently reported that mAB therapeutics sell for over $50 billion1 globally.
Howe...
More...
Friday 1st July 2016
Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (mABs), are playing an increasingly
important role in global healthcare. It was recently reported that mAB therapeutics sell for over $50 billion1 globally.
Howe...
More...
Friday 1st July 2016
COOKIES AND PERSONAL DATA:
This site does not use cookies.
However, it does securely hold details for those who register an account.
This information is only used by JPAG as described in the Privacy Statement (see link on footer below).
Follow us:
| Call us: | CONTACT US | Follow us: | | Terms and Conditions Privacy Statement |
| © Joint Pharmaceutical Analysis Group 2016 Website by Delta Consultancy Services |
|